A Phase III Double-blind, Placebo-controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Trial Profile

A Phase III Double-blind, Placebo-controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms coBRIM
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 16 Jun 2017 Planned End Date changed from 1 Dec 2017 to 28 Dec 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 12 Apr 2017 Results of expanded safety analysis (n=493, data cut-off date: 30 Sep 2015), published in the Annals of Oncology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top